Theralase Anti-Cancer Technology Validated in Prestigious US Chemistry Publication
27 5월 2014 - 7:59PM
Access Wire
Toronto, Ontario / ACCESSWIRE / May 27,
2014 / Theralase Technologies Inc.
("Theralase') (TSXV: TLT)
(TLTFF: OTCBB) announced today that its latest
research on Photo Dynamic Compound (PDC) technology, proven
effective in the destruction of bacteria and cancer, was peer
reviewed and invited to be published in the prestigious US Elsevier
publication, Coordination Chemistry
Reviews.
The new research presents how Theralase's new class of
PDCs incorporates systems that act as dual Type I/II
PDCs (able to work in oxygenated and non-oxygenated tissue),
opening up the possibility of treating hypoxic (low oxygen) tumours
with Photo Dynamic Therapy (PDT). These PDCs are remarkable
in-vitro centromere binders (localizing to the nucleus of a cell)
and photocleavers (ability to damage nucleus), thus destroying
cells when exposed to light. They also exhibit no nucleic damage in
the absence of light, supporting their high safety and
tolerability. This PDT effect translates effectively to animals and
has proven superior to the FDA approved PDC
Photofrin(R), in this research. The
ability to activate the Theralase PDCs from visible to Near Infra
Red (NIR) light marks an unprecedented versatility that can be
exploited to match treatment depth to tumour target depth, giving
rise to PDCs for multi-wavelength activated PDT.
Photo Dynamic Therapy (PDT) is an elegant method for
destroying cancer cells. PDCs accumulate in cells intended for
destruction and when light activated destroy the intended cell;
hence, PDT is best described as a combination therapy that offers
selectivity through local interactions between a PDC, light and
oxygen. Briefly, light absorption by the PDC produces a reactive
excited state that can participate in electron (Type I) or energy
(Type II) transfer to ground state molecular oxygen forming either
superoxide radical anions or cytotoxic singlet oxygen,
respectively. The production of a cytotoxic (cell killing) burst of
Reactive Oxygen Species (ROS), notably singlet oxygen has proven
effective in eliminating tumours and/or tumour vasculature. The
primary advantage of light-based approaches in treating diseases,
such as cancer, is that guided light delivery confines drug
activity to malignant sites; thereby, reducing collateral damage to
surrounding healthy tissue. Consequently, due to the
high photostability of the Theralase PDC, very low drug doses can
be used (nanograms) with activation at higher light doses,
simultaneously eliminating the side effects caused by
conventional systemic chemotherapeutics, such as
cisplatin.
Dr. Arkady Mandel, Chief Scientific Officer of Theralase
stated, "A number of successful efforts have been made by
Theralase's research team to satisfy the clinical requirements and
to improve the pharmaceutical and therapeutic properties of the
original PDCs. The results of our collaborative
research with Dr. Lothar Lilge's scientific team at Princess
Margaret Cancer Centre, University Health (UHN) and Dr. Sherri
McFarland's chemistry team at Acadia University (Acadia) reveal an
unprecedented versatility and efficacy of the Theralase's PDCs. The
research data published in the high impact journal Coordination
Chemistry Reviews may lead to development of the first-line of
patient specific PDT. I am delighted that Theralase has established
a very strong partnership with UHN and Acadia to progress this
pivotal technology to the next milestone, the completion of an
orthotopic animal model for bladder cancer. Together with clinical
guidance by Dr. Michael Jewett, a Professor of Surgery (Urology) at
the University of Toronto and one of the lead
clinician investigators and uro-oncologists at UHN, our
research provides excellent preclinical support to
Theralase to finalize the regulatory submissions and prepare us for
a Phase 1/2a human clinical trial to evaluate the technology in
patients inflicted with bladder cancer."
Dr. Lothar Lilge PhD, Professor in the Department of
Medical Biophysics at the University of Toronto, Senior Scientist,
Princess Margaret Cancer Centre, University Health Network stated
that the, "Publication of our research in Coordination Chemistry
Reviews validates the importance of the efforts of Acadia
University and UHN, with the fully committed support of Theralase,
in developing a novel approach for the destruction of solid
tumours, preferably in a single administration, thus
significantly improving the quality of life of cancer
patients. The results obtained to date provide strong support and
encouragement to complete the small outstanding preclinical work at
UHN to properly position this exciting technology for human
clinical studies at the earliest feasible point in
time."
Dr. Sherri McFarland PhD, Professor of Chemistry at Acadia University stated
that, "I am delighted to work with a strong partner such as
Theralase in the development of these PDCs that I originally
invented and optimized with the support of my partners. These PDCs
have proven to be very potent compounds in the destruction of
cancer cells in very small doses and I am excited to lead the
development of the PDCs and be part of the team completing the
preclinical work in 2014 to support human clinical studies in early
2015."
Roger Dumoulin-White,
President and CEO of Theralase stated that, "Coordination Chemistry
Reviews is a highly renowned publication known for publishing
chemistry research of the highest calibre. It is an honour for this
cutting-edge research to be recognized in a publication of this
level, further lending credence to the importance of the cancer
research we are undertaking with our partners, UHN and Acadia.
Targeting cancer cells regardless of tissue depth, enables
Theralase to customize its patented technology to be "patient
specific" to destroy cancer regardless of where it may reside in
the body."
About Theralase Technologies Inc.
Theralase Technologies Inc.
designs, manufactures and markets patented, superpulsed laser
technology used in eliminating pain and destroying cancer.
Theralase technology is safe and effective in eliminating pain,
reducing inflammation and accelerating tissue regeneration of
numerous nerve, muscle and joint conditions. Theralase
is actively developing patented technology that is able to target
and destroy cancers, bacteria and viruses, when light
activated.
Additional information is
available at www.theralase.com and
www.sedar.com .
This press release contains
forward-looking statements, which reflect the Company's current
expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could
differ materially from those projected herein. The Company
disclaims any obligation to update these forward-looking
statements.
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchanges) accepts responsibility for
the adequacy or accuracy of this release.
For More Information:
Roger Dumoulin-White
President & CEO, Theralase Technologies
Inc.
1.866.THE.LASE (843-5273) ext. 225
416.699.LASE (5273) ext. 225
rwhite@theralase.com
www.theralase.com
Arkady Mandel
Chief Scientific Officer, Theralase
Technologies Inc.
1.866.THE.LASE (843-5273) ext. 260
416.699.LASE (5273) ext. 260
amandel@theralase.com
www.theralase.com
SOURCE: Theralase Technologies Inc.
Theralase Technologies (TSXV:TLT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Theralase Technologies (TSXV:TLT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024